Merck's Keytruda wins breakthrough head and neck cancer nod around surgery, but with a limitation

13th June 2025 Uncategorised 0

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the indication is limited to PD-L1-positive disease.

More: Merck's Keytruda wins breakthrough head and neck cancer nod around surgery, but with a limitation
Source: fierce